107 related articles for article (PubMed ID: 9885984)
1. TP53 gene mutations in plasma DNA of cancer patients.
Silva JM; Gonzalez R; Dominguez G; Garcia JM; España P; Bonilla F
Genes Chromosomes Cancer; 1999 Feb; 24(2):160-1. PubMed ID: 9885984
[TBL] [Abstract][Full Text] [Related]
2. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
3. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis.
Tessitore A; Di Rocco ZC; Cannita K; Ricevuto E; Toniato E; Tosi M; Ficorella C; Frati L; Gulino A; Marchetti P; Martinotti S
Genes Chromosomes Cancer; 2002 Sep; 35(1):86-91. PubMed ID: 12203794
[TBL] [Abstract][Full Text] [Related]
4. TP53 gene in blood plasma DNA of tumor patients.
Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
[TBL] [Abstract][Full Text] [Related]
5. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations.
Silva JM; Dominguez G; Garcia JM; Gonzalez R; Villanueva MJ; Navarro F; Provencio M; San Martin S; España P; Bonilla F
Cancer Res; 1999 Jul; 59(13):3251-6. PubMed ID: 10397273
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract][Full Text] [Related]
7. The role of TP53 in breast cancer development.
Eeles RA; Bartkova J; Lane DP; Bartek J
Cancer Surv; 1993; 18():57-75. PubMed ID: 8013000
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
9. Mutations in Tp53 gene sequences from lung tumors in rats that inhaled plutonium dioxide.
Yamada Y; Oghiso Y
Radiat Res; 1999 Dec; 152(6 Suppl):S107-9. PubMed ID: 10564948
[TBL] [Abstract][Full Text] [Related]
10. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
11. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K; Rannala B; Traisathit P; Srikummool M; Wongchai Y; Kangwanpong D
Cancer Genet Cytogenet; 2008 Aug; 185(1):20-7. PubMed ID: 18656689
[TBL] [Abstract][Full Text] [Related]
12. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival.
Silva JM; Silva J; Sanchez A; Garcia JM; Dominguez G; Provencio M; Sanfrutos L; Jareño E; Colas A; España P; Bonilla F
Clin Cancer Res; 2002 Dec; 8(12):3761-6. PubMed ID: 12473587
[TBL] [Abstract][Full Text] [Related]
13. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.
Langerød A; Bukholm IR; Bregård A; Lønning PE; Andersen TI; Rognum TO; Meling GI; Lothe RA; Børresen-Dale AL
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1684-8. PubMed ID: 12496062
[TBL] [Abstract][Full Text] [Related]
14. Loss of TP53-DNA interaction induced by p.C135R in lung cancer.
Aranda M; Gonzalez-Nilo F; Riadi G; Díaz V; Perez J; Martel G; Hainaut P; Mimbacas A
Oncol Rep; 2007 Nov; 18(5):1213-7. PubMed ID: 17914575
[TBL] [Abstract][Full Text] [Related]
15. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
16. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
17. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
18. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
19. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.
Kleivi K; Diep CB; Pandis N; Heim S; Teixeira MR; Lothe RA
J Pathol; 2005 Sep; 207(1):14-9. PubMed ID: 16007576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]